Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity.
Rahmioglu N., Heaton J., Clement G., Gill R., Surdulescu G., Zlobecka K., Hodgkiss D., Smith NW., Ahmadi KR.
Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity-induced and inhibited-is thought to be the driver of numerous poor or adverse therapeutic responses to up to 50 % of all commonly prescribed drugs. We carried out a genome-wide association study to identify common genetic variants associated with variation in induced CYP3A4 activity. A total of 310 twins were included in this study. Each participant had already completed a 14 days course of St John's Wort to induce CYP3A4, which was quantified through the metabolic ratio of exogenous 3-hydroxyquinine to quinine. We failed to detect any genome-wide significant associations (P